Key Takeaways
- • Three biotech IPOs led the week's activity, with Hemab Therapeutics (COAG) raising $302 million at an $849 million valuation and closing up 89%, Avalyn Pharma (AVLN) raising $300 million at an $813 million valuation and closing up 66%, and Seaport Therapeutics (SPTX) raising $255 million at a $1.1 billion valuation and closing up 10%.
- • Hemab Therapeutics, focused on coagulation disorder treatments, advanced its lead candidate sutacimig (HMB-001) to Phase 3 readiness for Glanzmann thrombasthenia, while Avalyn Pharma's inhaled antifibrotic therapies are in Phase 2b/2 trials with topline data expected in mid- to late-2027.
- • Exploration-stage mining company Silver Bow Mining (SBMT) raised $60 million at a $368 million valuation but closed down 7%, owning 3,347 acres of patented mineral claims in Montana focused on silver, zinc, gold, lead, and copper extraction without current revenue generation.
- • Four traditional IPOs were accompanied by 11 blank check listings, underscoring continued SPAC activity as the April IPO market drew to a close alongside notable venture capital debuts.
- • Bill Ackman's Pershing Square USA, a significant capital markets event, closed its first day of trading down 18% despite raising $5 billion, indicating volatility in high-profile institutional fund debuts.
Summary
The U.S. IPO market closed out April with four traditional listings led by a trio of biotechnology companies demonstrating strong first-day performance across therapeutic areas. Hemab Therapeutics and Avalyn Pharma both upsized their offerings and priced at the high end, signaling robust institutional demand for early-to-mid stage development-stage biotech assets.
Hemab Therapeutics, developing antibody-based therapies for inherited bleeding disorders, raised $302 million at an $849 million market capitalization and experienced an 89% first-day gain. The company's lead candidate, sutacimig (HMB-001), has completed Phase 2 development and is positioned to advance into Phase 3 trials for Glanzmann thrombasthenia while pursuing Phase 2 evaluation for Factor VII deficiency. Avalyn Pharma, focused on inhaled antifibrotic therapies for rare respiratory diseases, raised $300 million at an $813 million valuation with a 66% first-day appreciation. The company's pipeline centers on AP01, currently in a global Phase 2b trial for progressive pulmonary fibrosis, and AP02, in Phase 2 for idiopathic pulmonary fibrosis, with topline data anticipated in mid- to late-2027.
Seaport Therapeutics, developing neuropsychiatric therapeutics, completed the biotech trio by raising $255 million at a $1.1 billion market cap, though with more modest first-day gains of 10%. The company's lead programs include GlyphAllo in Phase 2b for major depressive disorder and GlyphAgo in Phase 1 for generalized anxiety disorder, alongside preclinical candidates targeting additional CNS indications.
In the commodities space, exploration-stage mining company Silver Bow Mining raised $60 million at a $368 million valuation but traded down 7% on its debut. The company owns approximately 3,347 acres of patented mineral claims in Silver Bow County, Montana, with a focus on silver, zinc, gold, lead, and copper extraction, though it remains pre-revenue.
The week concluded April IPO activity alongside 11 blank check listings and the debut of Bill Ackman's Pershing Square USA, which raised $5 billion but closed its first trading day down 18%, reflecting market complexity surrounding large institutional fund launches.
Hemab Therapeutics, developing antibody-based therapies for inherited bleeding disorders, raised $302 million at an $849 million market capitalization and experienced an 89% first-day gain. The company's lead candidate, sutacimig (HMB-001), has completed Phase 2 development and is positioned to advance into Phase 3 trials for Glanzmann thrombasthenia while pursuing Phase 2 evaluation for Factor VII deficiency. Avalyn Pharma, focused on inhaled antifibrotic therapies for rare respiratory diseases, raised $300 million at an $813 million valuation with a 66% first-day appreciation. The company's pipeline centers on AP01, currently in a global Phase 2b trial for progressive pulmonary fibrosis, and AP02, in Phase 2 for idiopathic pulmonary fibrosis, with topline data anticipated in mid- to late-2027.
Seaport Therapeutics, developing neuropsychiatric therapeutics, completed the biotech trio by raising $255 million at a $1.1 billion market cap, though with more modest first-day gains of 10%. The company's lead programs include GlyphAllo in Phase 2b for major depressive disorder and GlyphAgo in Phase 1 for generalized anxiety disorder, alongside preclinical candidates targeting additional CNS indications.
In the commodities space, exploration-stage mining company Silver Bow Mining raised $60 million at a $368 million valuation but traded down 7% on its debut. The company owns approximately 3,347 acres of patented mineral claims in Silver Bow County, Montana, with a focus on silver, zinc, gold, lead, and copper extraction, though it remains pre-revenue.
The week concluded April IPO activity alongside 11 blank check listings and the debut of Bill Ackman's Pershing Square USA, which raised $5 billion but closed its first trading day down 18%, reflecting market complexity surrounding large institutional fund launches.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.